|Bid||80.05 x 100|
|Ask||84.11 x 100|
|Day's Range||80.85 - 81.54|
|52 Week Range||69.35 - 89.72|
|PE Ratio (TTM)||22.35|
|Earnings Date||Feb 20, 2018|
|Forward Dividend & Yield||1.84 (2.27%)|
|1y Target Est||89.92|
The U.S. Food and Drug Administration on Monday proposed creating a new fast track to market for certain medical devices and a potential reduction in the amount of safety data required for approval. Commissioner Scott Gottlieb announced the proposal in a blog posted on the FDA's website. If implemented, it could save device companies millions of dollars in product testing and shave years off development times.
DUBLIN - December 8, 2017 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2018 third quarter cash dividend of $0.46 per ordinary share, representing a 7 percent increase ...
There are never any guarantees that past performance will equal future performance, but we are now just five weeks into the seasonally favorable November-April time of the year.
In fiscal 2Q18, Medtronic used a portion of its divestiture proceeds toward stock buybacks. The total share repurchases in the quarter came in at ~$568.0 million.
Runaway success for this pioneer of robot-assisted surgery has inspired a slew of competitors to enter the arena.
Medtronic provides solutions to hospitals, which translate the clinical value to economic value for these hospitals.
DUBLIN - December 1, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the Citi 2017 Global Healthcare Conference on Wednesday, December ...
Medtronic's TYRX-based infection reduction program is accelerating at a strong pace. The number of accounts under this contract tripled to around 900 hospitals in fiscal 2Q18.
In fiscal 2Q18, Medtronic's Restorative Therapies Group business registered year-over-year sales growth of ~2.0%, which came in below expectations due to the negative impact of Hurricane Maria.
Due to the disappointing fiscal 2Q18 results, Medtronic made a downward revision to its estimates for MITG sales growth in fiscal 2018 to 3.0%–3.5%.
Medtronic's CVG (Cardiac and Vascular Group) business reported growth of ~7.0% on a YoY (year-over-year) basis.
Medtronic (MDT) reported net adjusted profits of ~$1.5 billion for fiscal 2Q18, an ~7.0% year-over-year decline. This report included an ~3.0% negative impact resulting from Hurricane Maria.
BD (BDX) has always focused on providing innovative products and solutions to its customers. The company makes considerable R&D (research and development) investments. In fiscal 4Q17, BD invested approximately ...
Boston Scientific dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge.
NEW YORK, Nov. 28, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Starbucks ...
Stock Monitor: Medtronic Post Earnings Reporting LONDON, UK / ACCESSWIRE / November 28, 2017 / Active-Investors' free earnings report on Boston Scientific Corp. (NYSE: BSX ) has freshly been issued to ...
Medtronic Care Management Services Delivers on Its Commitment to Serve Veteran Patients with Expanded Suite of Telehealth Solutions DUBLIN - November 27, 2017 - Medtronic plc (NYSE:MDT) today announced ...
As of November 23, 2017, the analysts' consensus target price for MDT for the next 12 months is $90.11, which represents an approximately 9.4% return on the basis of the stock's closing price of $82.3 ...